One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

(Reuters) -The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...

Merck MRK announced FDA approval for its prophylactic long ... While there are multiple vaccines approved for preventing RSV in the United States, the only one approved for immunizing infants ...

CHARLOTTE — The Food and Drug Administration approved a new vaccine to help protect infants from RSV on Monday. The treatment ...

RSV monoclonal antibody, clesrovimab,” which was approved by the FDA yesterday, Leerink Partners LLC analyst Daina Graybosch said. Insmed Inc.’s chair and CEO, Will Lewis, called the phase IIb trial ...